Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
Patients with diabetes are at increased risk of developing heart failure (HF) which can lead
to increased shortness of breath, reduced ability to exercise and in some cases premature
death as the heart becomes less efficient at pumping blood around the body. However the
treatment options for such patients remain limited.
This study will test the safety and benefits of using a new class of drug, the SGLT2
Inhibitor (Dapagliflozin), in treating HF and diabetes.
Participants will have a Magnetic Resonance Imaging (MRI) scan of the heart, to measure the
efficiency and the extent of thickening of the heart muscle before they start on treatment of
dapagliflozin, or placebo for one year. They will also do exercise testing on an exercise
bike (if capable) and a walking test plus fill in some questionnaires on how their heart
failure affects their quality of life. Participants will then continue as normal with
currently prescribed medication for their diabetes and heart failure. After a year the tests
will be repeated to determine if patients receiving Dapagliflozin benefited more than those
who weren't on the drug.
This study is funded by the European Foundation for the Study of Diabetes (EFSD)